Teleflex (NYSE:TFX – Get Free Report) posted its quarterly earnings data on Thursday. The medical technology company reported $2.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.90 by $0.73, FiscalAI reports. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The business had revenue of $567.80 million during the quarter, compared to the consensus estimate of $565.52 million. During the same period in the prior year, the firm earned $3.67 EPS. Teleflex’s quarterly revenue was up .1% compared to the same quarter last year.
Here are the key takeaways from Teleflex’s conference call:
- Teleflex reported 3.0% pro forma adjusted constant-currency revenue growth and adjusted EPS of $2.63, up 39.2% year over year. It raised 2026 adjusted EPS guidance to $7.50–$7.75 while maintaining revenue growth guidance of 3.5%–4.5%; the EPS outlook includes a $0.31 benefit from tariff refunds.
- Vascular and Surgical delivered solid growth of 4.6% and 5.1%, respectively, while Interventional returned to slight growth at 0.2%. Interventional remains affected by integration disruptions, though management reported progress in customer conversions, distributor transitions, and filling sales vacancies and expects gradual improvement.
- The Acute Care and Interventional Urology divestiture remains subject to an FTC review following a Second Request, and its closing could slip from the targeted year-end timing into 2027. Teleflex said it remains confident in completing the transaction but acknowledged that the timing is outside its control.
- Management expects a stronger financial profile in 2027, including operating margins of approximately 23% in the first year after the divestiture closes and lower interest expense and share count from debt reduction and buybacks. These improvements depend in part on completing the transaction and executing cost-saving and stranded-cost mitigation plans.
- Teleflex sees EZPLAZ as a long-term opportunity with a U.S. market potential of at least $200 million, but expects immaterial revenue in 2026 and a contribution in 2027 as it builds the market and scales production. The company also highlighted progress on its Freesolve scaffold trials and increased R&D investment, while noting that the product’s data readout is still expected in late 2027.
Teleflex Stock Performance
TFX stock traded down $1.26 on Friday, reaching $150.89. 948,142 shares of the company were exchanged, compared to its average volume of 718,324. The firm has a market capitalization of $6.39 billion, a PE ratio of 18.33, a PEG ratio of 0.94 and a beta of 0.85. Teleflex has a 12 month low of $100.18 and a 12 month high of $156.67. The stock’s fifty day moving average price is $132.15 and its 200 day moving average price is $126.09. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.60 and a quick ratio of 2.12.
Teleflex Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Monday, November 16th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Monday, November 16th. This represents a $1.36 dividend on an annualized basis and a yield of 0.9%. Teleflex’s payout ratio is -5.84%.
More Teleflex News
Here are the key news stories impacting Teleflex this week:
- Positive Sentiment: Royal Bank of Canada raised its price target to $175 from $155 and maintained an “outperform” rating, implying about 16% upside from the cited share price. Royal Bank of Canada rating
- Positive Sentiment: Wells Fargo increased its target to $167 from $138, while keeping an “equal weight” rating. Mizuho also raised its target, to $160. Wells Fargo rating Mizuho price target
- Positive Sentiment: Adjusted third-quarter EPS of $2.63 topped analyst estimates of about $1.90. Revenue of $567.8 million also narrowly exceeded expectations. Third-quarter results and outlook
- Neutral Sentiment: Teleflex declared a quarterly dividend of $0.34 per share, equivalent to $1.36 annually and a yield of about 0.9%. Dividend announcement
- Negative Sentiment: Revenue grew only 0.2% year over year, and adjusted EPS fell from $3.67 a year earlier. The modest reported growth may limit enthusiasm despite the earnings beat. Third-quarter results and outlook
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the stock. Royal Bank Of Canada boosted their target price on shares of Teleflex from $155.00 to $175.00 and gave the stock an “outperform” rating in a research report on Friday. Zacks Research cut shares of Teleflex from a “strong-buy” rating to a “hold” rating in a report on Friday, October 23rd. Piper Sandler reaffirmed an “overweight” rating and issued a $169.00 price target (up from $160.00) on shares of Teleflex in a research report on Friday, August 7th. Mizuho set a $160.00 price objective on Teleflex in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research note on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Teleflex has an average rating of “Moderate Buy” and an average target price of $160.80.
View Our Latest Research Report on TFX
About Teleflex
Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.
The company’s portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.
Read More
- Five stocks we like better than Teleflex
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
